Advanced Adult Hepatocellular Carcinoma

Oncology
4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
1 program
1
ENMD-2076Phase 21 trial
Active Trials
NCT02234986CompletedEst. Jun 2018
M&
Merck & Co.RAHWAY, NJ
1 program
1
Dalantercept plus sorafenibPhase 1/2Small Molecule1 trial
Active Trials
NCT02024087CompletedEst. Sep 2017
Ionis Pharmaceuticals
1 program
1
AZD9150Phase 1
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD9150Phase 11 trial
Active Trials
NCT01839604Completed58Est. Feb 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CASI PharmaceuticalsENMD-2076
Merck & Co.Dalantercept plus sorafenib
AstraZenecaAZD9150

Clinical Trials (3)

Total enrollment: 58 patients across 3 trials

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Start: Oct 2015Est. completion: Jun 2018
Phase 2Completed
NCT02024087Merck & Co.Dalantercept plus sorafenib

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Start: Aug 2014Est. completion: Sep 2017
Phase 1/2Completed

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Start: May 2013Est. completion: Feb 201558 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space